{"protocolSection": {"identificationModule": {"nctId": "NCT01440517", "orgStudyIdInfo": {"id": "GE-078-101"}, "organization": {"fullName": "GE Healthcare", "class": "INDUSTRY"}, "briefTitle": "Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction", "officialTitle": "An Open-Label, Multicenter, Proof of Concept, Phase 2 Study Evaluating the Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF)"}, "statusModule": {"statusVerifiedDate": "2014-01", "overallStatus": "TERMINATED", "whyStopped": "Lack of Subject Recruitment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2012-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-09-22", "studyFirstSubmitQcDate": "2011-09-23", "studyFirstPostDateStruct": {"date": "2011-09-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-30", "resultsFirstSubmitQcDate": "2014-01-02", "resultsFirstPostDateStruct": {"date": "2014-02-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-01-02", "lastUpdatePostDateStruct": {"date": "2014-02-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GE Healthcare", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF) will be enrolled and imaged with 99mTc maraciclatide. In addition, a maximum of 10 subjects with DM and diastolic dysfunction but no diagnosis of heart failure (HF) will be enrolled and imaged with 99mTc-maraciclatide."}, "conditionsModule": {"conditions": ["Diabetes Mellitus", "Heart Failure"], "keywords": ["CE-MRI - Contrast-enhanced magnetic resonance imaging", "DM - Diabetes mellitus", "EKG - Echocardiography", "HFPEF - Heart failure preserved left ventricular ejection fraction", "LVEF - Left Ventricular Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 4, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tc99m-Maraciclatide", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Tc99m-Maraciclatide"]}], "interventions": [{"type": "DRUG", "name": "Tc99m-Maraciclatide", "description": "Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection", "armGroupLabels": ["Tc99m-Maraciclatide"], "otherNames": ["Maraciclatide (99mTc) Injection"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Evidence of Active Myocardial Angiogenesis/Remodeling", "description": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "timeFrame": "Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration."}], "secondaryOutcomes": [{"measure": "Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction", "description": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "timeFrame": "Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The subject is between 18 and 80 years of age.\n* The subject was diagnosed with DM type 2 based upon accepted clinical criteria and currently takes at least one diabetes medication.\n* For HF subjects: The subject was diagnosed with HF with preserved EF within the previous 1 year, at which time LVEF was determined to be \u226545%.\n* For comparison subjects: The subject was determined to have diastolic dysfunction on EKG within the previous year and currently has no signs or symptoms of HF.\n* The subject has been clinically stable for at least 7 days prior to the study imaging procedures (e.g., not experiencing continuing chest pain, hemodynamic instability, worsening HF symptoms, or clinically significant arrhythmia).\n\nExclusion Criteria:\n\n* The subject had an acute myocardial infarction within the past 30 days.\n* The subject had a cardiac revascularization (e.g., percutaneous transluminal coronary angiography \\[PTCA\\], percutaneous coronary intervention (PCI), or coronary artery bypass graft \\[CABG\\]) within the past 30 days.\n* The subject has severe renal dysfunction.\n* The subject is claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to 20 minutes at a time.\n* The subject has participated in a research study using ionizing radiation in the previous 12 months.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Arnold Jacobson, MD", "affiliation": "GE Healthcare", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GE Healthcare", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Tc99m-Maraciclatide Injection", "description": "The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Subject withdrawn prior to dosing", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Tc99m-Maraciclatide Injection", "description": "The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.5", "spread": "4.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Evidence of Active Myocardial Angiogenesis/Remodeling", "description": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "populationDescription": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration.", "groups": [{"id": "OG000", "title": "Tc99m-Maraciclatide Injection", "description": "The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction", "description": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "populationDescription": "Due to the lack of subject enrollment, efficacy data were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration.", "groups": [{"id": "OG000", "title": "Tc99m-Maraciclatide Injection", "description": "The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Tc99m-Maraciclatide Injection", "description": "The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures).", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 2, "otherNumAtRisk": 4}], "otherEvents": [{"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Diabetes Mellitus-Inadequate Control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Arnold Jacobson, M.D.", "organization": "GE Healthcare", "email": "Arnold.Jacobson@ge.com", "phone": "1-609-514-6325"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}}, "hasResults": true}